Skip to content
Clinical Trials – home

Diabeteszentrum Hamburg West

Verified siteinfo

Germany Beselerstrasse 2a, 22607 Hamburg, Germany

  • 9 trials recruiting
  • Obesity · Type 2 diabetes mellitus · Overweight
  • Adult patients

About Specializations

Diabeteszentrum Hamburg West in Hamburg, Germany specialises in clinical trials of conditions such as Obesity, Type 2 diabetes mellitus, Overweight, Arteriosclerosis, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Diabeteszentrum Hamburg West, clinical research in cardiovascular diseases focuses on reducing major heart and blood vessel risks in people with atherosclerotic cardiovascular disease, heart failure, and related metabolic conditions. The trials are exploring new ways to lower LDL cholesterol and lipoprotein(a), while also evaluating whether emerging therapies can help prevent serious events such as heart attack and stroke.

  • Testing new treatments to lower cardiovascular risk in people with established heart and vessel disease
  • Studying therapies aimed at reducing LDL-C and lipoprotein(a) levels
  • Evaluating whether investigational approaches can help prevent major adverse cardiovascular events

This area includes research on ASCVD, prevention of heart failure, and broader strategies to improve long-term cardiovascular outcomes in patients with high risk.

Nutritional and Metabolic Diseases

The site conducts extensive studies in nutritional and metabolic diseases, especially obesity, overweight, and type 2 diabetes. Much of the work is centered on helping people achieve meaningful weight loss, improve glycemic control, and manage obesity-related complications through new treatment options.

  • Investigating therapies for weight loss in adults with overweight or obesity
  • Evaluating treatments for type 2 diabetes mellitus and improved blood sugar control
  • Studying approaches for people with obesity and related comorbidities

Research here also includes people living with type 1 diabetes, chronic weight management needs, and obesity linked to other health conditions, with the goal of improving everyday disease control and overall metabolic health.

Respiratory Tract Diseases

Research in respiratory tract diseases at this Hamburg site is strongly linked to obstructive sleep apnea, particularly in people who also have overweight or obesity. These studies are examining whether new therapies can improve sleep apnea severity while also supporting weight reduction and better overall health.

  • Studying treatment options for adults with obstructive sleep apnea and excess body weight
  • Assessing whether new therapies can improve the Apnea-Hypopnea Index
  • Exploring combined benefits for sleep-related breathing problems and weight management

The research includes both treated and untreated sleep apnea populations, reflecting a practical effort to improve symptoms and support better long-term outcomes in people with overlapping metabolic and respiratory disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Beselerstrasse 2a22607 HamburgGermany
Recruiting now
9 trials
Conditions studied
6
Partner status
Verified site

More sites in HamburgGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

17 clinical trials

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Phase III randomized trial of elecoglipron to assess safety and weight loss in adults with obesity or overweight, with or without type 2 diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

A study to evaluate the effectiveness and safety of eloralintide in adults with obesity or overweight without type 2 diabetes.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Obesity+1

Not yet recruiting

Phase 3 Double‑Blind Study of Olatorepatide for Weight Loss in Adults with Overweight or Obesity Without Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Regeneron Pharmaceuticals Inc.

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of zenagamtide in people with obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
  • Sponsor:Novo Nordisk A/S
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.